ABSTRACT
Background The association between chronic kidney disease (CKD) and the risk of developing venous thromboembolism (VTE) or pulmonary embolism (PE) is still controversial. Further, it is unknown if genetic predisposition modifies these relationships. This work aimed to investigate plausible effect modification of genetic factors on the association between CKD and incident VTE, as well as incident PE.
Methods Population-based cohort study of the UK Biobank, including participants of European ancestry that were free of VTE (397,658 participants) or PE (406,486 participants) at recruitment. We used cystatin C combining creatinine estimated glomerular filtration rate and albuminuria to classify the participants as the low, intermediate, and high or very high-risk groups suggested by KDIGO. Cox proportional hazards model was applied to evaluate the associations of CKD with incident VTE and PE. In addition, we used an externally validated polygenic risk score (PRS) for VTE to evaluate whether the genetic predisposition modified the associations of interest.
Results During median follow-up of 12.7 years, 11,372 participants developed VTE, and 6,518 participants developed PE. As compared with the low KDIGO risk category, covariate-adjusted hazard ratios (HR) and 95% confidence intervals (CI) for VTE risk with the intermediate KDIGO risk category and high or very high KDIGO risk category at baseline were 1.278 (1.191-1.372) and 1.892 (1.658-2.159), respectively. Participants at high or very high KDIGO risk category and in the highest tertile of PRS had the highest risk of developing VTE (HR, 4.397; 95% CI, 3.639-5.313), and this group showed the most conspicuous additive interaction between CKD and the genetic predisposition, which was responsible for 1.389-fold relative excess risk and 31.6% of the VTE risk. Also, when either estimated glomerular filtration rate or urine albumin-creatinine ratio was treated as the exposure, consistent associations were observed. Analyses for PE yielded similar associations and supra-additive interactions.
Conclusions CKD is associated with future VTE and PE, especially in those with high genetic risk.
What is new?
We observed that chronic kidney disease is associated with future venous thromboembolism and pulmonary embolism independently, irrespective of genetic predisposition.
We found considerable additive interaction between chronic kidney disease and genetic predisposition for future venous thromboembolism or pulmonary embolism risk.
What are the clinical implications?
It is essential to evaluate kidney condition in primary prevention of venous thromboembolism and pulmonary embolism.
Individuals with high genetic risk of venous thromboembolism might be the most relevant population to implement a personalized program of chronic kidney disease prevention, screening, and management.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
JZ, ZX, and XH were supported by grants from the San-Ming Project of Medicine, Shenzhen (SZSM201812097); YS was supported by National Natural Science Foundation of China (82204148) and Scientific Research Foundation of Peking University Shenzhen Hospital (KYQD2022203); JJC was supported by the Swedish Research Council (#2019-01059); and XH was supported by the Shenzhen Science and Technology Innovation Commission (grant No JCYJ20200109140412476). The funders had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UK Biobank obtained ethics approval from the North West Multi-Centre Research Ethics Committee (11/NW/0382)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The UK Biobank resource is available to bona fide researchers for health-related research in the public interest. All researchers who wish to access the research resource must register with UK Biobank by completing the registration form in the Access Management System
